Evaluating the systemic effects of RSPRY1 mutations in larger cohorts of SEMD patients is essential for establishing the broader phenotypic spectrum and for identifying potential therapeutic targets. The gene discussed is RSPRY1; the disease is spondyloepimetaphyseal dysplasia.